Canaccord Genuity Downgrades Synageva BioPharma (GEVA) to Hold
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/22/2026
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- BofA's Hartnett sees dollar slump, risk selloff if bond intervention fails
- Applied Optoelectronics sets up $600M at-the-market stock offering
- Fannie Mae loses at least 10 senior executives amid departures - WSJ
- Wall St rises on the day but falls for the week; bond yields and Iran in focus
- One killed, three injured when man attacks Swedish school with sword
- Morgan Stanley course-corrects their semiconductor equipment outlook on demand
Nomura Securities Downgrades Synageva BioPharma (GEVA) to Neutral Amid Takeover
May 7, 2015 8:54 AM EDTNomura Securities downgraded Synageva BioPharma (NASDAQ: GEVA) from Buy to Neutral with a price target of $230.00 following the takeover deal.
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $203.39 yesterday.
... MoreBaird Downgrades Synageva BioPharma (GEVA) to Neutral
May 7, 2015 8:35 AM EDTBaird downgraded Synageva BioPharma (NASDAQ: GEVA) from Outperform to Neutral with a price target of $217.00 (from $115.00).
For an analyst ratings summary and ratings history on Synageva BioPharma click here. For more ratings news on Synageva BioPharma click here.
Shares of Synageva BioPharma closed at $203.39 yesterday.
... MoreAlexion Pharma (ALXN) to Acquire Synageva BioPharma (GEVA) for $230/Share
May 6, 2015 6:40 AM EDTAlexion Pharma (NASDAQ: ALXN) and Synageva BioPharma Corp. (Nasdaq: GEVA) announced that they have entered into a definitive agreement pursuant to which Alexion will acquire Synageva for consideration of $115 in cash and 0.6581 Alexion shares, for each share of Synageva, implying a total per share value of $230 based on the nine day volume-weighted average closing price of Alexion stock through May 5, 2015. The acquisition strengthens Alexions global leadership in developing and commercializing transformative therapies for patients with devastating and rare diseases.
The transaction has been unanimously approved by both... More
